Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jun;63(6):627–633. doi: 10.1136/ard.2003.011395

Appropriate and effective management of rheumatoid arthritis

F Breedveld 1, J Kalden 1
PMCID: PMC1755045  PMID: 15140767

Full Text

The Full Text of this article is available as a PDF (142.1 KB).

Figure 1 .

Figure 1

Open in a new tab

Altering the course of RA. Reproduced with permission of the copyright holder, J Smolen.

Figure 2 .

Figure 2

Open in a new tab

Achieving remission in patients with RA through improved tools, processes, and goals. Reproduced with permission of the copyright holder, J Smolen.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aletaha D., Eberl G., Nell V. P. K., Machold K. P., Smolen J. S. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis. 2002 Jul;61(7):630–634. doi: 10.1136/ard.61.7.630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aletaha D., Smolen J. S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002 Dec;41(12):1367–1374. doi: 10.1093/rheumatology/41.12.1367. [DOI] [PubMed] [Google Scholar]
  3. Aletaha Daniel, Smolen Josef S. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 2002 Aug;29(8):1631–1638. [PubMed] [Google Scholar]
  4. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  5. Boers M., Verhoeven A. C., Markusse H. M., van de Laar M. A., Westhovens R., van Denderen J. C., van Zeben D., Dijkmans B. A., Peeters A. J., Jacobs P. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309–318. doi: 10.1016/S0140-6736(97)01300-7. [DOI] [PubMed] [Google Scholar]
  6. Choi Hyon K., Hernán Miguel A., Seeger John D., Robins James M., Wolfe Frederick. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002 Apr 6;359(9313):1173–1177. doi: 10.1016/S0140-6736(02)08213-2. [DOI] [PubMed] [Google Scholar]
  7. Danieli M. G., Malcangi G., Palmieri C., Logullo F., Salvi A., Piani M., Danieli G. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002 Jan;61(1):37–41. doi: 10.1136/ard.61.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dougados Maxime, Smolen Josef S. Pharmacological management of early rheumatoid arthritis--does combination therapy improve outcomes? J Rheumatol Suppl. 2002 Nov;66:20–26. [PubMed] [Google Scholar]
  9. Emery P., Breedveld F. C., Dougados M., Kalden J. R., Schiff M. H., Smolen J. S. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002 Apr;61(4):290–297. doi: 10.1136/ard.61.4.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Feldmann M., Brennan F. M., Maini R. N. Rheumatoid arthritis. Cell. 1996 May 3;85(3):307–310. doi: 10.1016/s0092-8674(00)81109-5. [DOI] [PubMed] [Google Scholar]
  11. Feldmann M., Brennan F. M., Maini R. N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397. [DOI] [PubMed] [Google Scholar]
  12. Feldmann M., Miotla J., Paleolog E., Williams R., Malfait A. M., Taylor P., Brennan F. M., Maini R. N. Future prospects for anti-cytokine treatment. Ann Rheum Dis. 2000 Nov;59 (Suppl 1):i119–i122. doi: 10.1136/ard.59.suppl_1.i119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fries J. F. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I86–I89. doi: 10.1136/ard.58.2008.i86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fries J. F., Williams C. A., Morfeld D., Singh G., Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996 Apr;39(4):616–622. doi: 10.1002/art.1780390412. [DOI] [PubMed] [Google Scholar]
  15. Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Antoni C. E., Bijlsma J. W. J., Burmester G. R., Cronstein B., Keystone E. C., Kavanaugh A. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis. 2002 Nov;61 (Suppl 2):ii2–ii7. doi: 10.1136/ard.61.suppl_2.ii2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gabriel S. E., Crowson C. S., Campion M. E., O'Fallon W. M. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol. 1997 Jan;24(1):43–48. [PubMed] [Google Scholar]
  17. Genovese Mark C., Bathon Joan M., Martin Richard W., Fleischmann Roy M., Tesser John R., Schiff Michael H., Keystone Edward C., Wasko Mary Chester, Moreland Larry W., Weaver Arthur L. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443–1450. doi: 10.1002/art.10308. [DOI] [PubMed] [Google Scholar]
  18. Goldsmith C. H., Boers M., Bombardier C., Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol. 1993 Mar;20(3):561–565. [PubMed] [Google Scholar]
  19. Kosinski M., Zhao S. Z., Dedhiya S., Osterhaus J. T., Ware J. E., Jr Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000 Jul;43(7):1478–1487. doi: 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  20. Krause D., Schleusser B., Herborn G., Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000 Jan;43(1):14–21. doi: 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  21. Landewé R., van der Heijde D. Follow up studies in rheumatoid arthritis. Ann Rheum Dis. 2002 Jun;61(6):479–481. doi: 10.1136/ard.61.6.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lard L. R., Visser H., Speyer I., vander Horst-Bruinsma I. E., Zwinderman A. H., Breedveld F. C., Hazes J. M. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001 Oct 15;111(6):446–451. doi: 10.1016/s0002-9343(01)00872-5. [DOI] [PubMed] [Google Scholar]
  23. Lindqvist E., Saxne T., Geborek P., Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis. 2002 Dec;61(12):1055–1059. doi: 10.1136/ard.61.12.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  25. Machold Klaus P., Stamm Tanja A., Eberl Gabriele J. M., Nell Valerie K. P., Dunky Attila, Uffmann Martin, Smolen Josef S. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol. 2002 Nov;29(11):2278–2287. [PubMed] [Google Scholar]
  26. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  27. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  28. Neidhart M., Rethage J., Kuchen S., Künzler P., Crowl R. M., Billingham M. E., Gay R. E., Gay S. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum. 2000 Dec;43(12):2634–2647. doi: 10.1002/1529-0131(200012)43:12<2634::AID-ANR3>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  29. O'Dell J. R., Haire C. E., Erikson N., Drymalski W., Palmer W., Eckhoff P. J., Garwood V., Maloley P., Klassen L. W., Wees S. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996 May 16;334(20):1287–1291. doi: 10.1056/NEJM199605163342002. [DOI] [PubMed] [Google Scholar]
  30. Pincus T., Brooks R. H., Callahan L. F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994 Jan 1;120(1):26–34. doi: 10.7326/0003-4819-120-1-199401010-00005. [DOI] [PubMed] [Google Scholar]
  31. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  32. Weinblatt Michael E., Keystone Edward C., Furst Daniel E., Moreland Larry W., Weisman Michael H., Birbara Charles A., Teoh Leah A., Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35–45. doi: 10.1002/art.10697. [DOI] [PubMed] [Google Scholar]
  33. Wolfe F., Hawley D. J. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998 Nov;25(11):2108–2117. [PubMed] [Google Scholar]
  34. Wolfe F., Mitchell D. M., Sibley J. T., Fries J. F., Bloch D. A., Williams C. A., Spitz P. W., Haga M., Kleinheksel S. M., Cathey M. A. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):481–494. doi: 10.1002/art.1780370408. [DOI] [PubMed] [Google Scholar]
  35. Wolfe F., Zwillich S. H. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum. 1998 Jun;41(6):1072–1082. doi: 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  36. Yelin E., Wanke L. A. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 1999 Jun;42(6):1209–1218. doi: 10.1002/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES